A 12-week, randomized, open-label study assessed the efficacy of nadifloxacin 1% cream or 4% erythromycin gel in 86 patients with mild-moderate facial acne. The treatments were applied twice daily for 12 weeks. Efficacy was assessed by lesion counts and the Acne Severity Index (ASI), which involved counts of pustules, papules and comedones. Both treatments significantly decreased both lesion counts and ASI, including its three separate components, over the 12-week period. Both treatments were equally effective, adverse events were mild-moderate and similar in both groups. Thus nadifloxacin and erythromycin are equally safe and effective in mild-moderate facial acne (Tunca, M. et al. Int J Dermatol 2010, 49: 1440).